PCM
KYNB

Piermont Capital Management’s Kyntra Bio KYNB Stock Holding History

Piermont Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200
Closed -$231K – 247
2018
Q1 		$231K Sell
200
-34
-15% -$44.8K 0.08% 228
2017
Q4 		$277K Sell
234
-149
-39% -$187K 0.09% 221
2017
Q3 		$515K Sell
383
-404
-51% -$426K 0.17% 155
2017
Q2 		$636K Buy
+787
New +$548K 0.18% 207

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Piermont Capital Management's KYNB Position: Q2 2018 in Review

Piermont Capital Management sold out of Kyntra Bio (KYNB) in Q2 2018, closing a stake of 200 shares — an estimated $231K sold.

Piermont Capital Management first reported a position in KYNB in Q2 2017 and held it in 4 quarters. The position peaked at $636K in Q2 2017. 192 funds tracked by Wall St. Rank hold KYNB as of Q2 2018.

  • Piermont Capital Management reported no remaining Kyntra Bio position as of Q2 2018 after selling out during the quarter.
  • Piermont Capital Management sold 200 Kyntra Bio shares in Q2 2018, an estimated $231K.
  • Piermont Capital Management first reported a position in Kyntra Bio in Q2 2017 and held it in 4 quarters.
  • Piermont Capital Management's Kyntra Bio position peaked at $636K in Q2 2017.
  • 192 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2018.

Based on Piermont Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.